Rapid recovery from acute myocarditis under levosimendan treatment: report of two cases

Ercan, Süleyman; Davutoğlu, Vedat; Cakici, Musa; Kus, Emre; Alıcı, Hayri; Sarı, İbrahim

doi:10.1111/jcpt.12038

Cited by 2 publications

(2 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In severely impaired ventricular function, there are anecdotal reports that intravenous levosimendan can improve biventricular function. 9 In our case, we observed a dramatic improvement from 25% to 40–45% of left ventricular ejection fraction during the hospital stay. However, our concern was the potential transient positive inotropic effect of levosimendan.…”

Section: Discussionsupporting

confidence: 54%

Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment

Fiore

Sanvito

Fragasso

et al. 2021

European Heart Journal - Case Reports

View full text Add to dashboard Cite

Background the year 2020 was dramatically characterized by SARS-CoV-2 pandemic outbreak. COVID-19-related heart diseases and myocarditis have been reported. Case summary a 45-year-old healthy male was admitted to the intensive care unit of our hospital because of cardiogenic shock. A diagnosis of COVID-19 infection and myocarditis was done. We present here several peculiarities about diagnostic workup, myocardial histological findings, choice of treatment and the patient clinical course at three and eight-months of follow-up. Discussion COVID-19 myocardial damage and myocarditis are mainly linked to the cytokine storm with mild myocardial inflammatory infiltrate and very unusual platelet microclots in the setting of the microvascular obstructive thrombo-inflammatory syndrome. Counteracting the inflammatory burden with an interleukine-1 inhibitor appeared safe and led to a dramatic and stable improvement of cardiac function.

show abstract

Section: Discussionsupporting

confidence: 54%

Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment

Fiore

Sanvito

Fragasso

et al. 2021

European Heart Journal - Case Reports

View full text Add to dashboard Cite

show abstract

“…And it may reduce the need for high-dose inotropes in another study [72]. There is no more evidence on levosimendan therapy for acute viral myocarditis [73, 74] and postpartum cardiomyopathy [75, 76] in humans to date.…”

Section: Introductionmentioning

confidence: 99%

Multiorgan Drug Action of Levosimendan in Critical Illnesses

Pan

Yang

Zhu

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Cardiotonic drugs mainly include digitalis, catecholamines, phosphodiesterase inhibitors, and calcium sensitizers, which have been successively discovered and applied in clinical practice. However, there are only a few new drugs available in this field, and the selection is very limited. Digitalis, catecholamines, and phosphodiesterase inhibitors increase myocardial contractility by increasing intracellular concentrations of cyclic adenosine monophosphate (cAMP) and Ca2+, and this increase in intracellular calcium ion concentration enhances myocardial oxygen consumption and causes arrhythmia. For these reasons, the research focus on positive inotropic agents has shifted from calcium mobilization to calcium sensitization. Intracellular calcium sensitizers are more effective and safer drugs because they do not increase the intracellular concentration of calcium ions. However, only three calcium sensitizers have been fully developed and used in the past three decades. One of these drugs, levosimendan, has multiple molecular targets and exerts its pharmacological effects by not only increasing myocardial contractility, but also enhancing respiratory muscle function and liver and kidney protection, and it is useful for patients with severe sepsis and septic shock. Recently, more than 60 randomized controlled clinical trials of levosimendan have been reported; however, these clinical trials have occasionally shown different findings. This article reviews the research progress of levosimendan in critical illnesses in recent years.

show abstract

Rapid recovery from acute myocarditis under levosimendan treatment: report of two cases

Abstract: To our knowledge, there is no report or study on levosimendan therapy for AVM in humans to date. Herein, we share two cases that revealed dramatic improvement in the myocardial function with levosimendan usage during the early phase of AVM.

Cited by 2 publications

References 13 publications

Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment

Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment

Multiorgan Drug Action of Levosimendan in Critical Illnesses

Contact Info

Product

Resources

About